Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

  • Revenue in EUR (TTM)6.59bn
  • Net income in EUR59.31m
  • Incorporated1987
  • Employees23.74k
  • Location
    Grifols SAC/ Jesus y Maria, 6BARCELONA 08022SpainESP
  • Phone+34 935710000
  • Fax+34 935710267
  • Websitehttps://www.grifols.com/
More ▼

Institutional shareholders

20.52%Per cent of shares held by top holders
HolderShares% Held
Brandes Investment Partners LPas of 31 Jan 202413.48m5.16%
The Vanguard Group, Inc.as of 30 Apr 20248.90m3.41%
Capital Research & Management Co. (World Investors)as of 31 Mar 20248.67m3.32%
Santander Asset Management SA SGIICas of 31 Dec 20238.06m3.08%
Capital International Ltd.as of 31 Mar 20246.24m2.39%
M&G Investment Management Ltd.as of 31 Jan 20243.09m1.18%
Robeco Institutional Asset Management BVas of 29 Mar 20241.70m0.65%
HSBC Global Asset Management (France) SAas of 30 Apr 20241.37m0.53%
Sabadell Asset Management SA SGIIC SUas of 31 Dec 20231.17m0.45%
FIL Investments Internationalas of 31 Jan 2024952.64k0.36%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.